ID

15767

Beskrivning

Treatment of Multiple Sclerosis Using Over the Counter Inosine; ODM derived from: https://clinicaltrials.gov/show/NCT00067327

Länk

https://clinicaltrials.gov/show/NCT00067327

Nyckelord

Versioner (1)
  1. 2016-06-12 2016-06-12 -
Uppladdad den

12 juni 2016

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Multiple Sclerosis, Relapsing-Remitting NCT00067327

Engelsk

Eligibility Multiple Sclerosis, Relapsing-Remitting NCT00067327

1 Formulär  
Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
nonpregnant, nonlactating females
Beskrivning

pregnancy or breast-feeding

Datatyp

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
females of child bearing potential must have a negative human chorionic gonadotropin (hcg) test result within 60 days before the first dose of study material.
Beskrivning

HCG test

Datatyp

boolean

Alias
UMLS CUI [1]
C0546577
males and females must practice adequate contraception, in the judgement of the investigator, during the course of the study.
Beskrivning

contraceptive methods

Datatyp

boolean

Alias
UMLS CUI [1]
C0700589
subjects must have a diagnosis of clinically definite relapsing remitting multiple sclerosis based on medical history, physical examination, laboratory test results, and neurologic examination. alternatively, subjects may have clinically probable ms characterized by 1 attack and the presence of at least 4 lesions on mri within 12 months before the initial baseline evaluation.
Beskrivning

relapsing remitting multiple sclerosis

Datatyp

boolean

Alias
UMLS CUI [1]
C0751967
subjects must have an expanded disability status scale (edss) test result of less than or equal to 5.0 within 60 days before the first dose of study material.
Beskrivning

EDSS

Datatyp

boolean

Alias
UMLS CUI [1]
C0451246
subjects will have serum uric acid levels less than 5 mg/dl.
Beskrivning

serum uric acid level

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0041980
UMLS CUI [1,2]
C0229671
have 1 clinical relapse in the last year
Beskrivning

clinical relapse

Datatyp

boolean

Alias
UMLS CUI [1]
C0856120
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
presence of any medical disability or laboratory test result that, in the judgement of the investigator, would interfere with assessment of the tolerability, safety, or efficacy of study material or would compromise the subject's ability to provide informed consent.
Beskrivning

comorbidity

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1321605
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
UMLS CUI [2]
C0009488
evidence of active infection characterized by requiring treatment with antibiotics within 7 days before the first dose of study material.
Beskrivning

evidence of active infection

Datatyp

boolean

Alias
UMLS CUI [1]
C0009450
treatment with interferons, glatiramer acetate, lymphoid irradiation, cyclophosphamide, or with other immune modifying treatments within 3 months, or corticosteroids within 1 month before the initial baseline mri assessment in this trial.
Beskrivning

treatment

Datatyp

boolean

Alias
UMLS CUI [1]
C0021747
UMLS CUI [2]
C0289884
UMLS CUI [3]
C0024230
UMLS CUI [4]
C0010583
recent history (within the previous 2 years) of drug or alcohol abuse.
Beskrivning

drug or alcohol abuse

Datatyp

boolean

Alias
UMLS CUI [1]
C0038586
known allergy to inosine products or history of anaphylaxis.
Beskrivning

allergy to inosine

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0021528
UMLS CUI [2]
C0002792
previous randomization into this study.
Beskrivning

previous randomization

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0034656
UMLS CUI [1,2]
C0205156
treatment with an investigational agent within 30 days before the first dose of study material.
Beskrivning

treatment with an investigational agent

Datatyp

boolean

Alias
UMLS CUI [1]
C2348568
Tillbaka till toppen

Similar models

Eligibility Multiple Sclerosis, Relapsing-Remitting NCT00067327

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
pregnancy or breast-feeding
Item
nonpregnant, nonlactating females
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
HCG test
Item
females of child bearing potential must have a negative human chorionic gonadotropin (hcg) test result within 60 days before the first dose of study material.
boolean
C0546577 (UMLS CUI [1])
contraceptive methods
Item
males and females must practice adequate contraception, in the judgement of the investigator, during the course of the study.
boolean
C0700589 (UMLS CUI [1])
relapsing remitting multiple sclerosis
Item
subjects must have a diagnosis of clinically definite relapsing remitting multiple sclerosis based on medical history, physical examination, laboratory test results, and neurologic examination. alternatively, subjects may have clinically probable ms characterized by 1 attack and the presence of at least 4 lesions on mri within 12 months before the initial baseline evaluation.
boolean
C0751967 (UMLS CUI [1])
EDSS
Item
subjects must have an expanded disability status scale (edss) test result of less than or equal to 5.0 within 60 days before the first dose of study material.
boolean
C0451246 (UMLS CUI [1])
serum uric acid level
Item
subjects will have serum uric acid levels less than 5 mg/dl.
boolean
C0041980 (UMLS CUI [1,1])
C0229671 (UMLS CUI [1,2])
clinical relapse
Item
have 1 clinical relapse in the last year
boolean
C0856120 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
comorbidity
Item
presence of any medical disability or laboratory test result that, in the judgement of the investigator, would interfere with assessment of the tolerability, safety, or efficacy of study material or would compromise the subject's ability to provide informed consent.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0009488 (UMLS CUI [2])
evidence of active infection
Item
evidence of active infection characterized by requiring treatment with antibiotics within 7 days before the first dose of study material.
boolean
C0009450 (UMLS CUI [1])
treatment
Item
treatment with interferons, glatiramer acetate, lymphoid irradiation, cyclophosphamide, or with other immune modifying treatments within 3 months, or corticosteroids within 1 month before the initial baseline mri assessment in this trial.
boolean
C0021747 (UMLS CUI [1])
C0289884 (UMLS CUI [2])
C0024230 (UMLS CUI [3])
C0010583 (UMLS CUI [4])
drug or alcohol abuse
Item
recent history (within the previous 2 years) of drug or alcohol abuse.
boolean
C0038586 (UMLS CUI [1])
allergy to inosine
Item
known allergy to inosine products or history of anaphylaxis.
boolean
C0020517 (UMLS CUI [1,1])
C0021528 (UMLS CUI [1,2])
C0002792 (UMLS CUI [2])
previous randomization
Item
previous randomization into this study.
boolean
C0034656 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
treatment with an investigational agent
Item
treatment with an investigational agent within 30 days before the first dose of study material.
boolean
C2348568 (UMLS CUI [1])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial